William Blair Estimates Sight Sciences Q1 Earnings

Sight Sciences, Inc. (NASDAQ:SGHT) – Investment analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Sight Sciences in a research report issued on Friday, May 9th. William Blair analyst M. Andrew expects that the company will earn ($0.27) per share for the quarter. The consensus estimate for Sight Sciences’ current full-year earnings is ($0.99) per share. William Blair also issued estimates for Sight Sciences’ Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.28) EPS and Q4 2026 earnings at ($0.24) EPS.

Other equities analysts have also recently issued research reports about the stock. UBS Group decreased their price target on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research report on Monday, January 27th. Stifel Nicolaus reduced their price objective on Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Wednesday, April 9th. Piper Sandler cut their price target on Sight Sciences from $5.50 to $3.50 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Finally, Citigroup decreased their price objective on Sight Sciences from $4.60 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.92.

Sight Sciences Trading Up 6.5%

Shares of SGHT stock opened at $3.42 on Monday. Sight Sciences has a fifty-two week low of $2.03 and a fifty-two week high of $8.45. The company has a 50 day moving average price of $2.72 and a 200 day moving average price of $3.20. The stock has a market capitalization of $176.80 million, a P/E ratio of -3.35 and a beta of 2.41. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. The company had revenue of $17.51 million for the quarter, compared to analyst estimates of $16.51 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%.

Insider Activity at Sight Sciences

In other Sight Sciences news, EVP Manohar K. Raheja acquired 10,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, with a total value of $27,300.00. Following the transaction, the executive vice president now owns 145,000 shares in the company, valued at $395,850. The trade was a 7.41% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Paul Badawi sold 24,174 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the completion of the transaction, the chief executive officer now owns 6,010,580 shares in the company, valued at approximately $13,824,334. The trade was a 0.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,196 shares of company stock valued at $81,001 over the last quarter. 30.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Sight Sciences

Several hedge funds have recently added to or reduced their stakes in SGHT. ProShare Advisors LLC purchased a new stake in shares of Sight Sciences during the 4th quarter worth approximately $36,000. Dynamic Technology Lab Private Ltd acquired a new stake in Sight Sciences during the 4th quarter worth $40,000. Arkadios Wealth Advisors purchased a new stake in Sight Sciences in the fourth quarter valued at $47,000. WealthTrust Asset Management LLC acquired a new position in Sight Sciences in the fourth quarter valued at $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Sight Sciences in the fourth quarter valued at $50,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.